Total Funding
37
66
Total FundingVenture - Series Unknown raised
Growth Score
-1 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
155074
BMG Pharma is a pharmaceuticals company and the first to develop patented biomaterials based on modified Sodium Hyaluronate.
- Paul Phull: Chief Commercial Officer
- Marco Mastrodonato: Founder and CEO
About the Company
BMG Pharma S.p.A.is an Italian pharmaceutical company and the first company in the world to develop products based on modified Sodium Hyaluronate, a patent protected technology which they brand as hyaluromimethic technology. BMG headquarters is currently located in Milan, Italy. It is a business to business company and its business model is based
on signing distribution and licensing agreements with companies worldwide to sell and distribute its products. In 2018, BMG acquired another Italian company, Sigea S.r.l, with expertise in the development of targeted functional ingredients, specifically focused on modified Hyaluronic Acid (Sodium Hyaluronate).
